Sulodexide oral administration influences blood viscosity and fibrinolysis.
The aim of this study was to verify the effects of oral administration of a new enteric-coated formulation of sulodexide on blood viscosity and fibrinolysis. Six outpatients suffering from peripheral artery occlusive disease were administered orally two enteric-coated tablets containing 50 mg of sulodexide, twice daily for seven days. On the first and seventh administration days, the following parameters were evaluated: plasminogen activator inhibitor (PAI-1) activity, PAI-1 antigen, tissue plasminogen activator (t-PA) and whole blood, serum and plasma viscosity, before (0 time) and 2, 4 and 8 hours after ingestion of the drug. Following the first administration (50 mg), a slight reduction of PAI was registered; after 7 days' administration, a clear-cut lowering of functional and antigenic PAI was observed, together with an increase of t-PA. As to the drug's influence on blood viscosity, after 7 days the most evident reduction was that registered for plasma viscosity. No side effects were observed throughout the treatment period.
Crepaldi
G
G
Department of 1st Medical Pathology, University of Padua, Italy.
Rossi
A
A
Coscetti
G
G
Abbruzzese
E
E
Calveri
U
U
Calabrò
A
A
D000368:Aged; D001809:Blood Viscosity / Q000187:drug effects*; D005260:Female; D005342:Fibrinolysis / Q000187:drug effects*; D006025:Glycosaminoglycans / Q000008:administration & dosage* / Q000494:pharmacology; D006801:Humans; D000960:Hypolipidemic Agents / Q000008:administration & dosage* / Q000494:pharmacology; D008297:Male; D008875:Middle Aged; D017395:Plasminogen Activator Inhibitor 1 / Q000032:analysis; D013608:Tablets, Enteric-Coated; D010959:Tissue Plasminogen Activator / Q000032:analysis
D006025:Glycosaminoglycans; D000960:Hypolipidemic Agents; D017395:Plasminogen Activator Inhibitor 1; D013608:Tablets, Enteric-Coated; C007858:glucuronyl glucosamine glycan sulfate; D010959:Tissue Plasminogen Activator